Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment.

ABSTRACT:

Background

Aripiprazole and risperidone, widely used atypical antipsychotics, are commonly adjunctively prescribed in clinical practice. When aripiprazole was combined with risperidone, the genotype of drug-metabolizing enzymes and liver impairment may lead to complex pharmacokinetic changes. The Physiologically Based Pharmacokinetic (PBPK) model can predict the influence of these factors on plasma concentration and optimize dosage regimens.

Objectives

This study aims to investigate the pharmacokinetic changes of aripiprazole caused by various influencing factors when it was co-administered with risperidone through PBPK models.

Design

The PBPK models of aripiprazole and risperidone were developed by gathering physicochemical parameters and drug-specific parameters. Th

SUBMITTER: Mou F 

PROVIDER: S-EPMC11656427 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature